Hervé Hoppenot, Incyte CEO

In­cyte se­cures sec­ond FDA ap­proval for bile duct can­cer drug in mu­tat­ed can­cer type

In­cyte nabbed its sec­ond ap­proval from fed­er­al reg­u­la­tors for can­cer drug pemi­ga­tinib, brand­ed as Pe­mazyre — as the po­ten­tial for even more in­di­ca­tions await.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.